Analogous to the total NSCLC cohort, CDKN2A/B alterations and cell cycle pathway alterations remained enriched in the BM LUAD group compared to PT and EM (CDKN2A/B: 31% vs 18%, p = 0.004, q = 0.14; cell cycle pathway: 52% vs 27%, p = 0.007, q = 0.072) (Suppl. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.